RT 4912 Review (A) Rex T. Christensen MHA RT (R) (MR) (CT) (ARRT) CIIP.
Do not duplicate or distribute without permission from ... · T1N0M0 > RT T1N1-3, T2-T4 any N 1....
Transcript of Do not duplicate or distribute without permission from ... · T1N0M0 > RT T1N1-3, T2-T4 any N 1....
NPC
Lisa Licitra
H&N Medical Oncology Dept
Istituto Nazionale dei Tumori
& University of Milan
ItalyDo not duplica
te or distr
ibute without
permiss
ion from author a
nd ESO
Former TYPE 1 Keratinizing squamous cell carcinoma (8071/3)
Former TYPE 2 Non keratinizing carcinomas (8072-3/3)
Differentiated non keratinizing carcinoma (8072-3/3)
Undifferentiated carcinoma (undifferentiated carcinoma of
nasopharyngeal type) (8020/3)
Former TYPE 3 Basaloid squamous cell carcinoma (8083/3)
Histological types WHO
25%
60%
12%
Do not duplicate or d
istribute without
permiss
ion from author a
nd ESO
EBV genomic variations are affected by: -geographic distributions, -environmentalinfluences-disease subtypes-phase of EBV latency
Do not duplicate or d
istribute without
permiss
ion from author a
nd ESO
NATURAL HISTORYGenetic, EBV latent infection, environmental carcinogenesis
Inherited (germline mut + EBV), endemic (gene polymorph + EBV) , sporadic(EBV + carcinogens)
Salted fish exp early life exposure, smoking
Familial cluster
M > F
40-60 peak age
Survival declining in EU!
Do not duplicate or d
istribute without
permiss
ion from author a
nd ESO
Prognostic factors
◼ Keratynisation
◼ TNM (supraclavicular nodes, masticatory space, T1
and T3)
◼ Tumor volume
◼ Gender F > M
◼ Age only in M
◼ QOL
◼ BMI
◼ IMRT
◼ Molecular: EGFR hx, p53 hx, PI3KCA, ERBB2, ERBB3
mut, miRNA, gene signature12/12/2018 6
Do not duplicate or d
istribute without
permiss
ion from author a
nd ESO
EBV-DNA testing
7
Screening for early NPC
Prognosis
Risk stratification for treatment
Disease surveillanceDo not duplica
te or distr
ibute without
permiss
ion from author a
nd ESO
- OS according to EBV DNA value
1 week post treatmentPre-treatment value
Prognostic/Predictive Factors
Do not duplicate or d
istribute without
permiss
ion from author a
nd ESO
2013
Plasma: DNA was extracted and EBV DNA copy number was determined by real-time quantitative PCR (BamHI-W primer/probe)Do not duplica
te or distr
ibute without
permiss
ion from author a
nd ESO
Do not duplicate or d
istribute without
permiss
ion from author a
nd ESO
11
Guidelines for delineation
Do not duplicate or d
istribute without
permiss
ion from author a
nd ESO
NCCN Guidelines 2018
12/12/2018 12
◼ T1N0M0 > RT
◼ T1N1-3, T2-T4 any N
1. Multimodality clinical trial
2. Concurrent CT/RT > Adjuvant CT
3. CT/RT (category 2B)
4. Induction > CT/RT (category 3b)
◼ M1
1. Trial
2. CT/RT
3. CT
Do not duplicate or d
istribute without
permiss
ion from author a
nd ESO
JNCI,2011Do not duplicate or d
istribute without
permiss
ion from author a
nd ESO
Do not duplicate or d
istribute without
permiss
ion from author a
nd ESO
12/12/2018 15
2018
Do not duplicate or d
istribute without
permiss
ion from author a
nd ESO
Do not duplicate or d
istribute without
permiss
ion from author a
nd ESO
Do not duplicate or d
istribute without
permiss
ion from author a
nd ESO
12/12/2018 18Do not duplica
te or distr
ibute without
permiss
ion from author a
nd ESO
Do not duplicate or d
istribute without
permiss
ion from author a
nd ESO
20
Do not duplicate or d
istribute without
permiss
ion from author a
nd ESO
12/12/2018 21Do not duplica
te or distr
ibute without
permiss
ion from author a
nd ESO
12/12/2018 22Do not duplica
te or distr
ibute without
permiss
ion from author a
nd ESO
12/12/2018 23Do not duplica
te or distr
ibute without
permiss
ion from author a
nd ESO
Hong Kong NPC Study Group 0502 Trial <br />(NCT00370890)
Presented By Anthony Chan at 2017 ASCO Annual Meeting
Do not duplicate or d
istribute without
permiss
ion from author a
nd ESO
Primary endpoint: Relapse free survival
Presented By Anthony Chan at 2017 ASCO Annual Meeting
Do not duplicate or d
istribute without
permiss
ion from author a
nd ESO
Overall survival in EBV DNA screening population
UICC stage
Post-RT plasma EBV DNA level
a) Post-RT plasma EBV DNA undetectable (=0 copy/ml)
b) Post-RT plasma EBV DNA detectable (>0 copy/ml)
IIB
III
IVAB
IIB
IIB
III
III
IVAB
IVAB
0
1-49
50-499
≥500
Do not duplicate or d
istribute without
permiss
ion from author a
nd ESO
Pts < 60 yrs
Excluded T3-T4N0
TPF at reduced doses (60-60-600)
Do not duplicate or d
istribute without
permiss
ion from author a
nd ESO
12/12/2018 28Do not duplica
te or distr
ibute without
permiss
ion from author a
nd ESO
12/12/2018 29Do not duplica
te or distr
ibute without
permiss
ion from author a
nd ESO
Neoadjuvant Chemotherapy Followed by Concurrent Chemoradiotherapy (NCRT+CCRT) Versus CCRT Alone in Locoregionally Advanced Nasopharyngeal Carcinoma
Presented By Ming-Yuan Chen at 2017 ASCO Annual Meeting
Excluded T3N0, N1 Do not duplicate or d
istribute without
permiss
ion from author a
nd ESO
Efficacy analysis
Presented By Ming-Yuan Chen at 2017 ASCO Annual Meeting
Do not duplicate or d
istribute without
permiss
ion from author a
nd ESO
Efficacy analysis
Presented By Ming-Yuan Chen at 2017 ASCO Annual Meeting
Do not duplicate or d
istribute without
permiss
ion from author a
nd ESO
Do not duplicate or d
istribute without
permiss
ion from author a
nd ESO
34
Do not duplicate or d
istribute without
permiss
ion from author a
nd ESO
35
Do not duplicate or d
istribute without
permiss
ion from author a
nd ESO
12/12/2018 36
CCR 2018
Do not duplicate or d
istribute without
permiss
ion from author a
nd ESO
Metastatic disease
◼ CDDP based RR 63-75%
◼ CDDP + Gem first line SOC
◼ Other active drugs: Taxanes, IFO, FU,
capecitabine,vinorelbine, gemcitabine , MTX, EDX,
cetuximab (11%)
◼ Non active drugs: TKI
◼ Immunotherapy: CTL, to disrupt EBV cell latency
(azactidine..), Nivo: 20% RR, PFS @1yr 19%
◼ Oligometastatic disease
12/12/2018 37Do not duplica
te or distr
ibute without
permiss
ion from author a
nd ESO
12/12/2018 38Do not duplica
te or distr
ibute without
permiss
ion from author a
nd ESO
12/12/2018 39
2018
Do not duplicate or d
istribute without
permiss
ion from author a
nd ESO
Conclusions
◼Rare disease
◼CT is beneficial in NPC
◼Refinement of pts selection for
neoadjuvant/adjuvant (?) CT based on
prognostic factors and biology
◼Biological agents
Do not duplicate or d
istribute without
permiss
ion from author a
nd ESO
Sinonasal
Cancers
Do not duplicate or d
istribute without
permiss
ion from author a
nd ESO
FACTS in EUIncidence
n/100.000
Survival @ 5 yrs
Epithelial nasal and
sinonasal cavity cancers
<1
SCC 50%
Lymphoepithelial 27%
SNUC 34%
ITAC 50%
Salivary gland tumor
types
69%
http://www.rarecare.eu/Do not duplica
te or distr
ibute without
permiss
ion from author a
nd ESO
WHO 2017Keratinising SCC
Non keratinising SCC
Spindle cell SCC
Lymphoepithelial
SNUC
NUT carcinoma
Neuroendocrine
Small cell neuroendocrine
Large cell neuroendocrine
Adenocarcinomas
ITAC
Non ITAC
TeratocarcinosarcomaDo not duplica
te or distr
ibute without
permiss
ion from author a
nd ESO
WHO 2017
• Sarcomas
• 12 subtypes
• Neuroectodermal tumors
• Ewing
• ONB (Hyams grading)
• MMDo not duplicate or d
istribute without
permiss
ion from author a
nd ESO
New described
epithelial entities• NUT midline carcinoma (NMC):
cromosome rearrangement
NUT/BRD4 + variants (NUT1
protein in IHC)
• HPV related carcinoma with
adenoid cystic like features (HPV
33)
• SMARCB1 (INI-1) deficient
Do not duplicate or d
istribute without
permiss
ion from author a
nd ESO
Am J Surg Pathol 2017Do not duplica
te or distr
ibute without
permiss
ion from author a
nd ESO
2018
Do not duplicate or d
istribute without
permiss
ion from author a
nd ESO
Cancer 2017
Do not duplicate or d
istribute without
permiss
ion from author a
nd ESO
Do not duplicate or d
istribute without
permiss
ion from author a
nd ESO
Do not duplicate or d
istribute without
permiss
ion from author a
nd ESO
Do not duplicate or d
istribute without
permiss
ion from author a
nd ESO
Do not duplicate or d
istribute without
permiss
ion from author a
nd ESO
2018
54 pts
Do not duplicate or d
istribute without
permiss
ion from author a
nd ESO
Which chemotherapy?
• Maximise localregional and distant sites effect
• Histotype driven
Do not duplicate or d
istribute without
permiss
ion from author a
nd ESO
Response to
induction CT
is a strong
prognostic factor
Median survival:
CR → 21+ months
PR → 13.5 months
NR → 3 months
Hanna 2010
Licitra 2003
Do not duplicate or d
istribute without
permiss
ion from author a
nd ESO
Bossi Cancer Treat Reviews 2015Do not duplica
te or distr
ibute without
permiss
ion from author a
nd ESO
Turri Zanoni Oral Oncol 2017Do not duplicate or d
istribute without
permiss
ion from author a
nd ESO
Do not duplicate or d
istribute without
permiss
ion from author a
nd ESO
First evidence: TP53 predict pCR to induction chemotherapy
Do not duplicate or d
istribute without
permiss
ion from author a
nd ESO
Functional p53 determinants of pCR
Do not duplicate or d
istribute without
permiss
ion from author a
nd ESO
Do not duplicate or d
istribute without
permiss
ion from author a
nd ESO
Do not duplicate or d
istribute without
permiss
ion from author a
nd ESO
Head and Neck 2016
SCC
Do not duplicate or d
istribute without
permiss
ion from author a
nd ESO
Multidisciplinary approach for poor prognosis sinonasal tumors:
Phase II study of chemotherapy, surgery, photon and heavy ion radiotherapy
integration for more effective and less toxic treatment in
operable and inoperable patients
SINTART1 (OPERABLE PATIENTS)
Study design:
Ph II, single-arm, open-label, multicenter studies
SINTART2 (INOPERABLE PATIENTS)
Study design:RC/RP >80%:
heavy ion based RT+ CT
no RC or RP <80%:
Surgery + Heavy ion based RT+CT
histology-driven CThistology-driven CT
heavy ion based
RT+ CT
AJCC stage: II-III-IVa
AJCC stage: Tb4
Sample size: 40 patients
Sample size: 25 patients
Primary endpoint: 5-yr PFS from 40 to 65%
Primary endpoint: 5-yr PFS
from 14% to 40%
Protocol: SINTART1 // SINTART2Sponsor: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano PI: Dott.ssa Lisa Licitra
Do not duplicate or d
istribute without
permiss
ion from author a
nd ESO
Conclusions
• WHO classification
• Multimodal therapeutic approach that
includes surgery, radiation and histotype
driven chemotherapy
• Biology to be exploited
• Multinational collaborationsDo not duplicate or d
istribute without
permiss
ion from author a
nd ESO